Ignite Creation Date:
2025-12-24 @ 2:17 PM
Ignite Modification Date:
2026-01-04 @ 8:37 AM
Study NCT ID:
NCT05211895
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2022-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-18
Start Date Type:
ACTUAL
Primary Completion Date:
2028-07-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-10-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-11
First Submit QC Date:
None
Study First Post Date:
2022-01-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-22
Last Update Post Date:
2025-12-23
Last Update Post Date Type:
ESTIMATED